Recently, Chinese scientists have made a significant breakthrough in overcoming cancer immune tolerance. A research team jointly formed by the Chinese Academy of Sciences and several leading medical institutions has successfully uncovered a novel regulatory mechanism capable of effectively disrupting the immunosuppressive tumor microenvironment, thereby enhancing T cells’ ability to recognize and eliminate cancer cells. Focusing on an immune checkpoint molecule called ‘LAG-3,’ the team developed a highly specific and high-affinity monoclonal antibody that significantly suppressed the growth of multiple solid tumors in animal models, with markedly fewer side effects compared to current therapies. Notably, when combined with PD-1 inhibitors, this antibody demonstrated strong synergistic effects, greatly improving treatment response rates. This discovery not only offers a new strategy to overcome resistance to immunotherapy but also lays the groundwork for next-generation anticancer drugs. Early-phase clinical trials are already underway, with the potential to benefit many cancer patients in the coming years. Experts note that this achievement marks China’s growing capacity for original innovation in the field of cancer immunotherapy, positioning it at the forefront of global research.
近日，中国科学家在攻克癌症免疫耐受领域取得重要突破。由中国科学院与多家顶尖医疗机构联合组成的研究团队，成功揭示了一种新型调控机制，能够有效打破肿瘤微环境中的免疫抑制状态，从而增强T细胞对癌细胞的识别与杀伤能力。该研究聚焦于一种名为‘LAG-3’的免疫检查点分子，并开发出一种高亲和力、高特异性的单克隆抗体，可在动物模型中显著抑制多种实体瘤的生长，且副作用明显低于现有疗法。更重要的是，该抗体与PD-1抑制剂联用时展现出协同效应，大幅提高治疗响应率。这一成果不仅为克服免疫治疗耐药性提供了新思路，也为开发下一代抗癌药物奠定了基础。目前，相关临床试验已进入早期阶段，有望在未来几年内惠及更多癌症患者。专家指出，这项研究标志着中国在肿瘤免疫治疗领域的原创能力正逐步走向国际前沿。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11083.html